Table 1 Metaplastic breast cancer cohort.
From: Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1
n | % | |
---|---|---|
Age | ||
<50 | 40 | 28.8 |
>51 | 99 | 71.2 |
Total | 139 | |
Size | ||
<2 cm | 31 | 21.4 |
2–5 cm | 82 | 56.6 |
>5 cm | 32 | 22.1 |
Total | 145 | |
WHO Type | ||
1 (mixed) | 116 | 71.6 |
2 (low‐grade adenosquamous) | 1 | 0.6 |
3 (fibromatosis‐like) | 4 | 2.5 |
4 (squamous) | 25 | 15.4 |
5 (spindle) | 14 | 8.6 |
6 (mesenchymal) | 2 | 1.2 |
Total | 162 | |
ER/PR/HER2 | ||
TNBC | 85 | 64.4 |
ER/PR pos | 8 | 6.1 |
ER pos | 13 | 9.8 |
PR pos | 13 | 9.8 |
HER2 pos | 13 | 9.8 |
Total | 132 | |
TILs | ||
Grp 1: 0–10% | 75 | 49.3 |
Grp 2: 20–40% | 62 | 40.8 |
Grp 3: 50–90% | 15 | 9.9 |
total | 152 | |
PD-L1 tumour cells | ||
Positive | 107 | 73 |
Negative | 39 | 27 |
Total | 146 | |
PD-L1 TILs | ||
Positive | 91 | 63 |
Negative | 53 | 37 |
Total | 144 | |
FOXP3 sTILs | ||
Positive | 73 | 49 |
Negative | 76 | 51 |
Total | 149 | |
FOXP3 iTILs | ||
Positive | 57 | 38 |
Negative | 93 | 62 |
Total | 150 |